Biogen Inc. (BIIB)
NASDAQ: BIIB
· Real-Time Price · USD
139.94
-1.68 (-1.19%)
At close: Sep 04, 2025, 3:59 PM
140.43
0.35%
Pre-market: Sep 05, 2025, 09:12 AM EDT
-1.19% (1D)
| Bid | 139.86 |
| Market Cap | 20.52B |
| Revenue (ttm) | 10B |
| Net Income (ttm) | 1.53B |
| EPS (ttm) | 10.45 |
| PE Ratio (ttm) | 13.39 |
| Forward PE | 8.96 |
| Analyst | Hold |
| Ask | 140.05 |
| Volume | 1,226,120 |
| Avg. Volume (20D) | 1,387,504 |
| Open | 141.78 |
| Previous Close | 141.62 |
| Day's Range | 137.14 - 142.28 |
| 52-Week Range | 110.04 - 205.19 |
| Beta | 0.13 |
About BIIB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BIIB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BIIB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Biogen Inc. is scheduled to release its earnings on
Oct 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
+5.6%
Biogen shares are trading higher after the company...
Unlock content with
Pro Subscription
1 month ago
+1.07%
Biogen shares are trading higher after the company reported better-than-expected Q2 results and raised its FY2025 adjusted EPS guidance above estimates.
1 month ago · seekingalpha.com
Biogen: Strong Q2 Doesn't Change The Math On Eroding MS PortfolioBiogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their ...